A new treatment to degrade androgen receptors in advanced prostate cancer
A novel AR degrader in castrate-resistant prostate cancer
This study is exploring a new way to help men with castrate-resistant prostate cancer by using special molecules that can remove the proteins that help the cancer grow, aiming to make existing treatments work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10907660 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic approach to treat castrate-resistant prostate cancer (CRPC) by targeting and degrading androgen receptors (AR) that contribute to cancer progression. The study utilizes innovative molecules called AUTOTACs, which link AR inhibitors to a system that promotes the degradation of AR proteins through autophagy. By effectively removing these receptors, the goal is to overcome resistance to current anti-androgen therapies and improve treatment outcomes for patients with CRPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castrate-resistant prostate cancer who have not responded to standard anti-androgen therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet developed resistance to androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that effectively targets and degrades androgen receptors, potentially improving survival and quality of life for patients with advanced prostate cancer.
How similar studies have performed: While the approach of targeting androgen receptor degradation is innovative, similar strategies in other cancers have shown promise, indicating potential for success in this area.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Kim, Hyeong-Reh Choi — Wayne State University
- Study coordinator: Kim, Hyeong-Reh Choi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.